Corporate Profile

We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With our product candidates, we aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule, for Alzheimer’s, Parkinson's disease dementia and dementia with Lewy bodies.

Data Provided by Refinitiv. Minimum 15 minutes delayed.